HDAC6 and hepatocellular carcinoma: PD-1 + B cells inhibit T cell expansion and viability, with PD-L1 blockade enhancing T cell proliferation and viability.538 HDAC6-depleted T cells stimulated PD-1/PD-L1 expression and synergistically sensitized advanced HCC to ICIs, suggesting potential for HCC immunotherapy.